Imatinib Discontinuation in Chronic Phase CML Doesn’t Always Lead to Relapse

By Dave Levitan June 14, 2013 Almost half of patients with chronic-phase chronic myeloid leukemia (CML) who discontinued imatinib(Drug information on imatinib) treatment did not relapse, according to results of a prospective study. Those who did relapse showed continued sensitivity to imatinib when treatment started again.